Duchenne muscular dystrophy

News

Santhera's DMD drug poised for wider rollout in Germany

Santhera has agreed pricing and reimbursement for its Duchenne muscular dystrophy drug Agamree with German health funds representing 90% of patients.

News

Wheelchair sign with trees in background

Santhera preps UK Duchenne drug launch after NICE says yes

Santhera will launch its new drug for Duchenne muscular dystrophy in the UK within the next few weeks after getting the green light for NHS coverage.

News

Capricor files cell therapy for DMD cardiomyopathy with FDA

Capricor completes its US filing for deramiocel, vying to become the first FDA-approved therapy for cardiomyopathy in Duchenne muscular dystrophy.

News

Price deal opens door to NHS use of Santhera DMD drug

Santhera's Duchenne muscular dystrophy (DMD) therapy Agamree has been cleared for NHS use after a confidential pricing agreement.

News

Gene therapy firm Kate Tx snapped up by Novartis for $1.1bn

Novartis buys gene therapy specialist Kate Therapeutics for $1.1 billion, adding an early-stage rival to Sarepta's muscular dystrophy therapy Elevidys

News

Sarepta pulls plug on Duchenne exon-skipping drug

Sarepta Therapeutics has decided not to continue the development of vesleteplirsen, a follow-up to its Duchenne muscular dystrophy (DMD) therapy Exondys 51.

Santhera's DMD drug poised for wider rollout in Germany

Santhera preps UK Duchenne drug launch after NICE says yes

Capricor files cell therapy for DMD cardiomyopathy with FDA

Price deal opens door to NHS use of Santhera DMD drug

Gene therapy firm Kate Tx snapped up by Novartis for $1.1bn

Sarepta pulls plug on Duchenne exon-skipping drug

NHS staff 'feel unprepared for digital transformation'

How to meet your physicians where they are online

Duchenne muscular dystrophy

Editor's Picks